Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-14 4:55 pm Sale | 13G | Revance Therapeutics, Inc. RVNC | Palo Alto Investors LP | 5,237,284 5.960% | -46,325 (-0.88%) | View |
| 2024-02-14 4:54 pm Purchase | 13G | eHealth, Inc. EHTH | Palo Alto Investors LP | 2,739,379 9.660% | 254,900 (+10.26%) | View |
| 2024-02-14 4:52 pm Sale | 13G | Karyopharm Therapeutics Inc. KPTI | Palo Alto Investors LP | 5,102,193 4.450% | -553,483 (-9.79%) | View |
| 2023-04-03 2:24 pm Sale | 13G | Alimera Sciences, Inc. ALIM | Palo Alto Investors LP | 0 0.000% | -802,423 (Position Closed) | View |
| 2023-02-14 4:23 pm Sale | 13G | Vanda Pharmaceuticals Inc. VNDA | Palo Alto Investors LP | 1,087,064 1.420% | -1,747,180 (-61.65%) | View |
| 2023-02-14 4:22 pm Purchase | 13G | Revance Therapeutics, Inc. RVNC | Palo Alto Investors LP | 5,283,609 6.420% | 914,243 (+20.92%) | View |
| 2023-02-14 4:21 pm Purchase | 13G | Karyopharm Therapeutics Inc. KPTI | Palo Alto Investors LP | 5,655,676 5.000% | 185,224 (+3.39%) | View |
| 2023-02-14 4:19 pm Sale | 13G | Insmed Incorporated INSM | Palo Alto Investors LP | 5,871,291 4.330% | -154,415 (-2.56%) | View |
| 2023-02-14 4:18 pm Sale | 13G | Epizyme, Inc. EPZM | Palo Alto Investors LP | 0 0.000% | -5,485,213 (Position Closed) | View |
| 2023-02-14 4:17 pm Purchase | 13G | eHealth, Inc. EHTH | Palo Alto Investors LP | 2,484,479 9.060% | 868,909 (+53.78%) | View |
| 2023-02-14 4:12 pm Unchanged | 13G | Alimera Sciences, Inc. ALIM | Palo Alto Investors LP | 802,423 11.450% | 0 (Unchanged) | View |
| 2022-02-14 5:11 pm Sale | 13G | Epizyme, Inc. EPZM | Palo Alto Investors LP | 5,485,213 5.280% | -1,253,700 (-18.60%) | View |
| 2022-02-14 5:09 pm Purchase | 13G | Karyopharm Therapeutics Inc. KPTI | Palo Alto Investors LP | 5,470,452 7.240% | 202,800 (+3.85%) | View |
| 2022-02-14 5:08 pm Sale | 13G | Vanda Pharmaceuticals Inc. VNDA | Palo Alto Investors LP | 2,834,244 5.090% | -1,396,304 (-33.01%) | View |
| 2022-02-14 5:07 pm Purchase | 13G | Alimera Sciences, Inc. ALIM | Palo Alto Investors LP | 802,423 11.570% | 802,423 (New Position) | View |
| 2022-02-14 5:04 pm Purchase | 13G | Revance Therapeutics, Inc. RVNC | Palo Alto Investors LP | 4,369,366 6.090% | 4,369,366 (New Position) | View |
| 2022-02-14 5:03 pm Sale | 13G | STAAR Surgical Company STAA | Palo Alto Investors LP | 1,140,511 2.400% | -1,708,837 (-59.97%) | View |
| 2022-02-14 5:01 pm Sale | 13G | Insmed Incorporated INSM | Palo Alto Investors LP | 6,025,706 5.090% | -80,274 (-1.31%) | View |
| 2022-02-14 4:59 pm Sale | 13G | CLOVIS ONCOLOGY INC CLVSQ | Palo Alto Investors LP | 3,997,826 3.080% | -471,585 (-10.55%) | View |
| 2022-02-14 4:57 pm Purchase | 13G | eHealth, Inc. EHTH | Palo Alto Investors LP | 1,615,570 6.120% | 1,615,570 (New Position) | View |